ArticleAmerican journal of translational research2025
Risk factors for new-onset atrial fibrillation in patients with acute myocardial infarction.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the incidence of new-onset atrial fibrillation (NOAF) and its related risk factors in patients with acute myocardial infarction (AMI), providing a scientific basis for clinical prevention and treatment.
methodsClinical data of 240 The First Hospital of Fangshan District between June 2022 and June 2024 were retrospectively analyzed. Patients were divided into a NOAF group (31 patients) and non-NOAF group (209 patients) according to whether NOAF occurred during hospitalization. Baseline data, laboratory test results, and imaging data of patients were collected. Independent risk factors for NOAF were screened by multifactorial logistic regression analysis and their predictive value was assessed by Receiver Operating Characteristic (ROC) curve. Model goodness of fit was evaluated using the calibration curve and Hosmer-Lemeshow test. The clinical efficacy of the model was evaluated by using the decision curve, accuracy, sensitivity, and specificity.
resultsThe incidence of NOAF in AMI patients was 12.92%. The NOAF group had significantly higher mean age, higher proportion of patients with a history of hypertension, higher Killip classification ≥ 2, larger left atrial diameter (LAD), and elevated troponin I (cTnI) levels compared to the non-NOAF group (P < 0.05). Multifactorial logistic regression analysis identified age (OR = 1.10, 95% CI: 1.03-1.17), history of hypertension (OR = 8.29, 95% CI: 2.81-24.43), cTnI level (OR = 1.35, 95% CI: 1.18-1.54), and LAD (OR = 1.34, 95% CI: 1.15-1.56) as independent risk factors for the development of NOAF in patients with AMI (P < 0.05). ROC curve analysis showed a high predictive efficacy for combining these four indicators, with an AUC of 0.973 (95% CI: 0.951-0.994). In addition, patients in the NOAF group had a longer mean length of stay and a significantly higher rate of adverse events than those in the non-NOAF group (P < 0.05).
conclusionThe occurrence of NOAF in AMI patients is associated with a variety of factors. Identifying these high-risk factors may help clinicians to identify patients at high risk of NOAF early, optimize management, and thusreduce the incidence and adverse outcomes of NOAF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.